Projects & Grants

Internal Grant Competition DGC
START-UP grant





Genomic profile of aberrant plasma cells in patients with multiple myeloma in state of minimal residual disease
Project IdSGS18/PřF/2017-2018
Main solverMgr. Martina Zátopková
Period1/2017 - 12/2018
ProviderSpecifický VŠ výzkum
Statefinished
AnotationMultiple myeloma is a serious oncological disease of the immune system associated with abnormal plasma cell production which subsequently produces an abnormal monoclonal protein in excesive amount. Myeloma cells are genetically heterogeneous. After frongline therapy, which relieves the patient of most myeloma cells, some of the myeloma cells can resist the treatment, persist in the minimal residual disease state and then cause relapse of the disease. For the complete elimination of these residual clones, it is essential to recognize their properties and to find some features that can be targeted by the treatment. The aim of this project is the characterization of exome of residual clones from patients with multiple myeloma in the stage of minimal residual disease in terms of mononucleotide polymorphism and its derived mutation profile. For this purpose new generation sequencing followed by bioinformatical analysis will be used. We use a pair samples from each patient - aberrant plasma cells that are sorted out from bone marrow by fluorescence activated flow cytometry, and peripheral blood to eliminate somatic variants. Variants which are unique in the aberrant population will be subject to annotation and analysis for the potential use of targeted therapy.